|
시장보고서
상품코드
2067692
스페셜티 제네릭 시장 규모, 점유율 및 동향 분석 보고서 : 유형별, 적응증별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)Specialty Generics Market Size, Share & Trends Analysis Report By Type (Injectables, Oral Drugs), By Indication (Oncology, Inflammatory conditions, Multiple sclerosis, Hepatitis C), By End Use, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
스페셜티 제네릭 시장 개요
세계의 스페셜티 제네릭 시장 규모는 2025년에 959억 8,000만 달러로 추계되며, 2033년까지 1,713억 6,000만 달러에 달할 것으로 예측됩니다.
2026-2033년 연평균 성장률(CAGR) 7.58%로 성장할 것으로 전망됩니다. 이 시장은 만성질환 및 희귀 질환으로 인한 부담의 증가와 비용 대비 효과가 높은 치료 옵션에 대한 수요에 힘입어 꾸준한 성장을 달성하고 있습니다.
이러한 의약품은 특히 종양학, 자가면역질환, 감염증 분야에서 환자들이 복잡한 치료법에 더 쉽게 접근할 수 있도록 하는 데 있으며, 매우 중요한 역할을 하고 있습니다. 제제 기술의 발전과 제네릭 의약품 승인을 위한 규제 당국의 지원이 시장 확대를 더욱 지원하고 있습니다. 또한 바이오시밀러와 고부가가치 주사용 제네릭 의약품에 대한 관심이 높아지면서 경쟁 구도가 재편되고 있습니다. 의료제도가 합리적인 가격과 접근성을 중시하는 가운데, 전문 제네릭 의약품은 지속가능한 의약품 관리의 중요한 구성 요소로 부상하고 있습니다.
세계보건기구(WHO)에 따르면 전 세계 고령자 인구는 급속히 확대되고 있으며, 최근 수년간 눈에 띄게 증가하고 있습니다. 2030년까지 총인구에서 차지하는 비율이 크게 증가하여, 60세 이상 인구가 6명 중 1명이 될 것으로 예측됩니다. 고령자는 장기적인 치료가 필요한 만성질환이나 복잡한 질환에 걸리기 쉬우므로, 이러한 인구 동향의 변화는 전문 제네릭 시장에서 큰 성장 기회를 창출할 것으로 전망됩니다. 또한 주요 기업은 시장내 입지를 강화하고 전문 제네릭 의약품 포트폴리오를 확대하기 위해 합병, 인수 및 전략적 제휴에 점점 더 주력하고 있습니다. 이러한 노력은 예측 기간 중 시장의 지속적인 성장을 지원할 것으로 전망됩니다.
그러나 오리지널 의약품에 대한 강한 브랜드 충성도, 전문 제네릭 의약품의 개발 및 제조에 필요한 복잡한 요건, 그리고 비교적 낮은 이익률은 신규 시장 진입 기업에게 큰 진입 장벽이 되고 있습니다. 이러한 과제들은 특정 부문에서 경쟁 제한이나 가격 압박으로 이어질 가능성이 있습니다. 또한 오리지널 의약품 제조사가 도입하는 환자 지원 프로그램이나 판촉 전략은 대개 환자가 오리지널 제품을 계속 사용하도록 유도하며, 그 결과 전문 제네릭 의약품의 채택 및 시장 침투에 영향을 미치고 있습니다.
자주 묻는 질문
목차
제1장 조사 방법과 범위
제2장 개요
제3장 스페셜티 제네릭 시장 : 변수, 동향, 범위
제4장 스페셜티 제네릭 시장 : 유형별 비즈니스 분석
제5장 스페셜티 제네릭 시장 : 적응증별 비즈니스 분석
제6장 스페셜티 제네릭 시장 : 최종 사용별 비즈니스 분석
제7장 스페셜티 제네릭 시장 : 지역별 추정·동향 분석
제8장 경쟁 구도
KSA 26.06.29Specialty Generics Market Summary
The global specialty generics market size was estimated at USD 95.98 billion in 2025 and is projected to reach USD 171.36 billion by 2033, growing at a CAGR of 7.58% from 2026 to 2033. The market is witnessing steady growth driven by the rising burden of chronic and rare diseases and the demand for cost-effective treatment alternatives.
These drugs play a crucial role in improving patient access to complex therapies, particularly in oncology, autoimmune disorders, and infectious diseases. Advancements in drug formulation technologies and regulatory support for generic approvals are further facilitating market expansion. Additionally, the growing focus on biosimilars and high-value injectable generics is reshaping the competitive landscape. As healthcare systems emphasize affordability and accessibility, specialty generics are emerging as a key component of sustainable pharmaceutical care.
According to the World Health Organization (WHO), the global geriatric population is expanding rapidly, rising significantly in recent years, and is projected to reach a substantial share of the total population by 2030, with one in six individuals aged 60 years and above. This demographic shift is expected to create significant growth opportunities in the specialty generics market, as older populations are more prone to chronic and complex diseases that require long-term treatment. In addition, leading pharmaceutical companies are increasingly focusing on mergers, acquisitions, and strategic collaborations to strengthen their market presence and expand their specialty generics portfolios. Such initiatives are anticipated to support sustained market growth over the forecast period.
However, strong brand loyalty toward innovator drugs, the complex development and manufacturing requirements of specialty generics, and relatively lower profit margins act as significant entry barriers for new market participants. These challenges can contribute to limited competition and pricing pressures in certain segments. Furthermore, patient assistance programs and promotional strategies adopted by branded drug manufacturers often enhance patient retention for original products, thereby impacting the uptake and market penetration of specialty generic alternatives.
Global Specialty Generics Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global specialty generics market report based on type, indication, end use, and region:
- Type Outlook (Revenue, USD Billion, 2021 - 2033)
- Injectables
- Oral drugs
- Others
- Indication Outlook (Revenue, USD Billion, 2021 - 2033)
- Oncology
- Inflammatory conditions
- Multiple sclerosis
- Hepatitis C
- Others
- End Use Outlook (Revenue, USD Billion, 2021 - 2033)
- Specialty pharmacy
- Retail pharmacy
- Hospital pharmacy
- Regional Outlook (Revenue, USD Billion, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Type
- 1.2.2. Indication
- 1.2.3. End Use
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market End Use & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Specialty Generics Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- 3.3.4. Patent Expiry Analysis
- 3.3.5. Pricing Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
Chapter 4. Specialty Generics Market: Type Business Analysis
- 4.1. Type Market Share, 2025 & 2033
- 4.2. Type Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Billion)
- 4.4. Injectables
- 4.4.1. Injectables Market, 2021 - 2033 (USD Billion)
- 4.5. Oral Drugs
- 4.5.1. Oral Drugs Market, 2021 - 2033 (USD Billion)
- 4.6. Others
- 4.6.1. Others Market, 2021 - 2033 (USD Billion)
Chapter 5. Specialty Generics Market: Indication Business Analysis
- 5.1. Indication Market Share, 2025 & 2033
- 5.2. Indication Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Billion)
- 5.4. Oncology
- 5.4.1. Oncology Market, 2021 - 2033 (USD Billion)
- 5.5. Inflammatory Conditions
- 5.5.1. Inflammatory Conditions Market, 2021 - 2033 (USD Billion)
- 5.6. Multiple Sclerosis
- 5.6.1. Multiple Sclerosis Market, 2021 - 2033 (USD Billion)
- 5.7. Hepatitis C
- 5.7.1. Hepatitis C Market, 2021 - 2033 (USD Billion)
- 5.8. Others
- 5.8.1. Others Market, 2021 - 2033 (USD Billion)
Chapter 6. Specialty Generics Market: End Use Business Analysis
- 6.1. End Use Market Share, 2025 & 2033
- 6.2. End Use Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Billion)
- 6.4. Specialty Pharmacy
- 6.4.1. Specialty Pharmacy Market, 2021 - 2033 (USD Billion)
- 6.5. Retail Pharmacy
- 6.5.1. Retail Pharmacy Market, 2021 - 2033 (USD Billion)
- 6.6. Hospital Pharmacy
- 6.6.1. Hospital Pharmacy Market, 2021 - 2033 (USD Billion)
Chapter 7. Specialty Generics Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2025 & 2033
- 7.2. Regional Market Dashboard
- 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
- 7.4. North America
- 7.4.1. North America Specialty Generics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
- 7.4.2. U.S.
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Target Disease Prevalence
- 7.4.2.3. Regulatory Framework
- 7.4.2.4. Reimbursement Framework
- 7.4.2.5. U.S. Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.4.3. Canada
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Target Disease Prevalence
- 7.4.3.3. Regulatory Framework
- 7.4.3.4. Reimbursement Framework
- 7.4.3.5. Canada Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.4.4. Mexico
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Target Disease Prevalence
- 7.4.4.3. Regulatory Framework
- 7.4.4.4. Reimbursement Framework
- 7.4.4.5. Mexico Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5. Europe
- 7.5.1. Europe Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.2. UK
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Target Disease Prevalence
- 7.5.2.3. Regulatory Framework
- 7.5.2.4. Reimbursement Framework
- 7.5.2.5. UK Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.3. Germany
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Target Disease Prevalence
- 7.5.3.3. Regulatory Framework
- 7.5.3.4. Reimbursement Framework
- 7.5.3.5. Germany Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.4. France
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Target Disease Prevalence
- 7.5.4.3. Regulatory Framework
- 7.5.4.4. Reimbursement Framework
- 7.5.4.5. France Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.5. Italy
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Target Disease Prevalence
- 7.5.5.3. Regulatory Framework
- 7.5.5.4. Reimbursement Framework
- 7.5.5.5. Italy Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.6. Spain
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Target Disease Prevalence
- 7.5.6.3. Regulatory Framework
- 7.5.6.4. Reimbursement Framework
- 7.5.6.5. Spain Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.7. Denmark
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Target Disease Prevalence
- 7.5.7.3. Regulatory Framework
- 7.5.7.4. Reimbursement Framework
- 7.5.7.5. Denmark Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.8. Sweden
- 7.5.8.1. Key Country Dynamics
- 7.5.8.2. Target Disease Prevalence
- 7.5.8.3. Regulatory Framework
- 7.5.8.4. Reimbursement Framework
- 7.5.8.5. Sweden Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.9. Norway
- 7.5.9.1. Key Country Dynamics
- 7.5.9.2. Target Disease Prevalence
- 7.5.9.3. Regulatory Framework
- 7.5.9.4. Reimbursement Framework
- 7.5.9.5. Norway Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6. Asia Pacific
- 7.6.1. Asia Pacific Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6.2. Japan
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Target Disease Prevalence
- 7.6.2.3. Regulatory Framework
- 7.6.2.4. Reimbursement Framework
- 7.6.2.5. Japan Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6.3. China
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Target Disease Prevalence
- 7.6.3.3. Regulatory Framework
- 7.6.3.4. Reimbursement Framework
- 7.6.3.5. China Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6.4. India
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Target Disease Prevalence
- 7.6.4.3. Regulatory Framework
- 7.6.4.4. Reimbursement Framework
- 7.6.4.5. India Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6.5. Australia
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Target Disease Prevalence
- 7.6.5.3. Regulatory Framework
- 7.6.5.4. Reimbursement Framework
- 7.6.5.5. Australia Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6.6. South Korea
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Target Disease Prevalence
- 7.6.6.3. Regulatory Framework
- 7.6.6.4. Reimbursement Framework
- 7.6.6.5. South Korea Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6.7. Thailand
- 7.6.7.1. Key Country Dynamics
- 7.6.7.2. Target Disease Prevalence
- 7.6.7.3. Regulatory Framework
- 7.6.7.4. Reimbursement Framework
- 7.6.7.5. Thailand Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.7. Latin America
- 7.7.1. Latin America Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.7.2. Brazil
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Target Disease Prevalence
- 7.7.2.3. Regulatory Framework
- 7.7.2.4. Reimbursement Framework
- 7.7.2.5. Brazil Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.7.3. Argentina
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Target Disease Prevalence
- 7.7.3.3. Regulatory Framework
- 7.7.3.4. Reimbursement Framework
- 7.7.3.5. Argentina Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.8. Middle East and Africa
- 7.8.1. Middle East and Africa Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.8.2. South Africa
- 7.8.2.1. Key Country Dynamics
- 7.8.2.2. Target Disease Prevalence
- 7.8.2.3. Regulatory Framework
- 7.8.2.4. Reimbursement Framework
- 7.8.2.5. South Africa Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.8.3. Saudi Arabia
- 7.8.3.1. Key Country Dynamics
- 7.8.3.2. Target Disease Prevalence
- 7.8.3.3. Regulatory Framework
- 7.8.3.4. Reimbursement Framework
- 7.8.3.5. Saudi Arabia Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.8.4. UAE
- 7.8.4.1. Key Country Dynamics
- 7.8.4.2. Target Disease Prevalence
- 7.8.4.3. Regulatory Framework
- 7.8.4.4. Reimbursement Framework
- 7.8.4.5. UAE Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.8.5. Kuwait
- 7.8.5.1. Key Country Dynamics
- 7.8.5.2. Target Disease Prevalence
- 7.8.5.3. Regulatory Framework
- 7.8.5.4. Reimbursement Framework
- 7.8.5.5. Kuwait Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 8. Competitive Landscape
- 8.1. Participant Overview
- 8.2. Company Market Position Analysis
- 8.3. Company Categorization
- 8.4. Strategy Mapping
- 8.5. Company Profiles/Listing
- 8.5.1. Teva Pharmaceuticals Industries Ltd
- 8.5.1.1. Overview
- 8.5.1.2. Financial Performance
- 8.5.1.3. Type Benchmarking
- 8.5.1.4. Strategic Initiatives
- 8.5.2. Viatris Inc.
- 8.5.2.1. Overview
- 8.5.2.2. Financial Performance
- 8.5.2.3. Type Benchmarking
- 8.5.2.4. Strategic Initiatives
- 8.5.3. Novartis AG (Sandoz International GmbH)
- 8.5.3.1. Overview
- 8.5.3.2. Financial Performance
- 8.5.3.3. Type Benchmarking
- 8.5.3.4. Strategic Initiatives
- 8.5.4. Hikma Pharmaceuticals PLC.
- 8.5.4.1. Overview
- 8.5.4.2. Financial Performance
- 8.5.4.3. Type Benchmarking
- 8.5.4.4. Strategic Initiatives
- 8.5.5. Mallinckrodt
- 8.5.5.1. Overview
- 8.5.5.2. Financial Performance
- 8.5.5.3. Type Benchmarking
- 8.5.5.4. Strategic Initiatives
- 8.5.6. Bausch Health Companies Inc. (Valeant Pharmaceuticals International, Inc.)
- 8.5.6.1. Overview
- 8.5.6.2. Financial Performance
- 8.5.6.3. Type Benchmarking
- 8.5.6.4. Strategic Initiatives
- 8.5.7. Dr. Reddy's Laboratories Ltd.
- 8.5.7.1. Overview
- 8.5.7.2. Financial Performance
- 8.5.7.3. Type Benchmarking
- 8.5.7.4. Strategic Initiatives
- 8.5.8. Endo Pharmaceuticals Inc.
- 8.5.8.1. Overview
- 8.5.8.2. Financial Performance
- 8.5.8.3. Type Benchmarking
- 8.5.8.4. Strategic Initiatives
- 8.5.9. Apotex Corp.
- 8.5.9.1. Overview
- 8.5.9.2. Financial Performance
- 8.5.9.3. Type Benchmarking
- 8.5.9.4. Strategic Initiatives
- 8.5.10. Sun Pharmaceutical Industries Ltd
- 8.5.10.1. Overview
- 8.5.10.2. Financial Performance
- 8.5.10.3. Type Benchmarking
- 8.5.10.4. Strategic Initiatives
- 8.5.1. Teva Pharmaceuticals Industries Ltd
